You are here: Industry Insights > Breast Cancer

News List

UK charity Breast Cancer Care receives £655,000 cash injection to expand end-of-treatment app pharmafile
February 01, 2018
UK charity Breast Cancer Care is set to expand the development of its end-of-treatment support app after receiving a £655,000 cash injection from the Big Lottery Fund, the country’s largest distributor of National Lottery money.
Puma Sinks After the CHMP Throws a Roadblock at Breast Cancer Drug biospace
January 25, 2018
Despite some safety concerns such as severe diarrhea, the U.S. Food and Drug Administration approved Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) in July 2017
FDA approves Lynparza to treat inherited breast cancer pharmaceutical-technology
January 17, 2018
The US Food and Drug Administration (FDA) has approved the use of AstraZeneca’s Lynparza for the treatment of certain types of breast cancer that have metastasized and those with BRCA gene mutation.
FDA approves first treatment for breast cancer with a certain inherited genetic mutation biospectrumasia
January 16, 2018
It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.
Dietary xenoestrogens may reduce effectiveness of breast cancer treatment europeanpharmaceuticalreview
January 12, 2018
A new study suggests breast cancer patients taking palbociclib/letrozole combination therapy should avoid foods rich in xenoestrogens…
Xcision receives FDA clearance for the GammaPod Stereotactic Radiotherapy System for breast cancer biospectrumasia
January 10, 2018
The delivery of higher doses in one or several large fractions differentiates stereotactic radiotherapy, also known as stereotactic body radiation therapy (SBRT), from conventional techniques.
TALAZOPARIB SIGNIFICANTLY EXTENDS PROGRESSION-FREE SURVIVAL IN PHASE 3 EMBRACA TRIAL OF PATIENTS WIT pfizer
December 11, 2017
Pfizer Inc. today announced that its Phase 3 EMBRACA trial of patients with reproductive BRCA1 / 2 positive locally advanced and / or metastatic breast cancer has demonstrated excellent progression-free survival
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint® and BluePri b3cnewswire
December 04, 2017
Agendia, Inc., a global leader in personalized medicine and molecular cancer diagnostics, announces the value of its upcoming MammaPrint®70-Breast Cancer Recurrence Risk Test and BluePrint® Breast Cancer Molecular Subtype Test at the upcoming 2017 San Ant
Specialised Therapeutics to commercialise Puma’s Nerlynx for breast cancer pharmaceutical-technology
November 28, 2017
Nerlynx is not yet approved for commercialization outside the United States.
EU invests €6.3m into cancer project led by Philips biospectrumasia
November 27, 2017
The project complements the €18.3m Cancer-ID project.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page